As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
7 Analysts have issued a Sol-Gel Technologies Ltd. forecast:
7 Analysts have issued a Sol-Gel Technologies Ltd. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 24 24 |
265%
265%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -4.59 -4.59 |
72%
72%
|
|
| EBIT (Operating Income) EBIT | -4.77 -4.77 |
72%
72%
|
|
| Net Profit | -3.41 -3.41 |
77%
77%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
| Head office | Israel |
| CEO | Moshe Arkin |
| Employees | 36 |
| Founded | 1997 |
| Website | www.sol-gel.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


